Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

This initiative aims to democratise art by showcasing approximately 600 artworks from hundreds of artists, offering a diverse ...

EBGLYSStm (lebrikizumab) developed by Eli Lilly and Co and Almirall | Atopic dermatitis EBGLYSStm, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab) and ...

We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

(Image Credits: Pixabay) It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. Zepbound’s superior efficacy and ...

Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. “The Huminsulin range ...

To QB or not to QB? That was the question Eli Stowers asked himself as the 2023 college football season approached for New Mexico State. The question answered itself. The answer not to QB.

Eli Lilly plans to launch the drug in India by 2025, pending approvals. The treatment is expected to be a breakthrough by aiding weight reduction, which in turn improves breathing during sleep.